Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...

New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...

ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...

GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer (PFE) and Shionogi (SGIOY) as ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today ...

The study found that N6LS (VH3810109 or VH109), given every four months in combination with already marketed monthly ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced new data from two implementation studies showing zero cases of HIV ...

The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.

ViiV Healthcare has announced promising results from two Phase IIa studies of investigational antiretroviral therapies, VH184 ...